Credit: Michigan medicine
Screening for a sometimes fatal condition among patients with a rare autoimmune disease could soon - thanks to a computer algorithm - become even more accurate.
Researchers at Michigan Medicine found that an internet application improved their ability to spot pulmonary arterial hypertension in patients with systemic sclerosis, or scleroderma. The unpredictable condition is marked by tightening of the skin that can damage internal organs.
The algorithm, aptly named DETECT, outperformed standard methods used to identify the form of high blood pressure in the lungs that causes the heart to weaken and fail. We ve been advocating for a long time that every scleroderma patient should be screened on an annual basis using DETECT, and this data supports that, says Dinesh Khanna, M.B.B.S., M.Sc., senior author of the study and director of Michigan Medicine s Scleroderma Program. Pulmonary arterial hypertension is a leading cause of death for these patients, an
E-Mail
PHILADELPHIA Humans have a uniquely high density of sweat glands embedded in their skin 10 times the density of chimpanzees and macaques. Now, researchers at Penn Medicine have discovered how this distinctive, hyper-cooling trait evolved in the human genome. In a study published today in the
Proceedings of the National Academy of Sciences of the USA, researchers showed that the higher density of sweat glands in humans is due, to a great extent, to accumulated changes in a regulatory region of DNA called an enhancer region that drives the expression of a sweat gland-building gene, explaining why humans are the sweatiest of the Great Apes.
CET- Comunicado - ;ultimaHoraHtml += + json.lead + ;}ultimaHoraHtml += ; document.getElementById( urgente ).innerHTML = ultimaHoraHtml; } } });
Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee
· With the acquisition of Mestex AG, Grünenthal secures global rights for an attractive late-stage asset that could offer an innovative therapy option for millions of patients affected by pain related to osteoarthritis of the knee.
· MTX-071 (resiniferatoxin) is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. Its administration can reversibly defunctionalise TRPV1-expressing nociceptors. This can result in long lasting pain relief.
Aachen, Germany, 12 April 2021 – Today, Grünenthal has announced the acquisition of Mestex AG through the takeover of all of
Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee realwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from realwire.com Daily Mail and Mail on Sunday newspapers.
(0) Primary study endpoint demonstrates 86 percent response rate for patients receiving co-therapy of KRYSTEXXA and mycophenolate mofetil
Horizon Therapeutics plc (Nasdaq: HZNP) announced the publication of data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomitantly used with an immunomodulator, mycophenolate mofetil, in
Arthritis Rheumatology [doi.org/10.1002/art.41731].
The Reducing Immunogenicity of Pegloticase (RECIPE) trial demonstrated that 86 percent of patients (19 of 22) receiving co-therapy of KRYSTEXXA with the immunomodulator mycophenolate mofetil achieved serum uric acid (sUA) 6 mg/dL at 12 weeks, the primary study endpoint, compared to 40 percent of patients (4 of 10) receiving KRYSTEXXA monotherapy. The safety and efficacy of KRYSTEXXA co-prescribed with mycophenolate mofetil has not been established by any health authorities.